Global Liquid Biopsy Technology 麻豆原创 Research Report 2023

Publication ID:

PB508239985

Publication Date:

August 31, 2023

Pages:

112

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Liquid biopsy technology is a non-invasive diagnostic approach that involves the analysis of biomarkers and genetic material (such as circulating tumor DNA or ctDNA) present in body fluids, primarily blood, to detect and monitor various diseases, especially cancer. Unlike traditional biopsies that involve invasive procedures to collect tissue samples, liquid biopsy offers a less invasive and potentially more convenient method for disease detection and monitoring.
The global Liquid Biopsy Technology market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Liquid Biopsy Technology market research.
The global market for liquid biopsy technology has been experiencing substantial growth in recent years, driven by the increasing prevalence of cancer and other chronic diseases, the demand for non-invasive diagnostic methods, and advancements in genomic research and personalized medicine. The demand for liquid biopsy technology varies across different regions, with key markets located in North America, Europe, Asia-Pacific, and other regions with a high burden of cancer and robust research infrastructure. North America, including the United States and Canada, has been a dominant market for liquid biopsy technology due to the presence of well-established healthcare systems, high incidence of cancer, and strong investment in medical research. The global market for liquid biopsy technology is expected to continue growing in the coming years, driven by ongoing advancements in genomic research, increasing adoption of personalized medicine, and the need for non-invasive diagnostic solutions.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Liquid Biopsy Technology market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Exact Sciences
Guardant Health
Natera
Bio-Techne
LabCorp
Endress+Hauser
MDxHealth
MutantDx
Thermo Fisher Scientific
Norgen Biotek
Nucleix
OraSure Technologies
Qiagen
Bio-Rad Laboratories
Biocartis
NeoGenomics
Sysmex Inostics
Menarini Silicon Biosystems
Biocept
ANGLE plc
Segment by Type
CTCs
ctDNA
Exosomes
Segment by Application
Blood Sample
Urine Sample
Other Bio Fluids
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Liquid Biopsy Technology report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Liquid Biopsy Technology 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 CTCs
1.2.3 ctDNA
1.2.4 Exosomes
1.3 麻豆原创 by Application
1.3.1 Global Liquid Biopsy Technology 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Blood Sample
1.3.3 Urine Sample
1.3.4 Other Bio Fluids
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liquid Biopsy Technology 麻豆原创 Perspective (2018-2029)
2.2 Liquid Biopsy Technology Growth Trends by Region
2.2.1 Global Liquid Biopsy Technology 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Liquid Biopsy Technology Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Liquid Biopsy Technology Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Liquid Biopsy Technology 麻豆原创 Dynamics
2.3.1 Liquid Biopsy Technology Industry Trends
2.3.2 Liquid Biopsy Technology 麻豆原创 Drivers
2.3.3 Liquid Biopsy Technology 麻豆原创 Challenges
2.3.4 Liquid Biopsy Technology 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liquid Biopsy Technology Players by Revenue
3.1.1 Global Top Liquid Biopsy Technology Players by Revenue (2018-2023)
3.1.2 Global Liquid Biopsy Technology Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Liquid Biopsy Technology 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Liquid Biopsy Technology Revenue
3.4 Global Liquid Biopsy Technology 麻豆原创 Concentration Ratio
3.4.1 Global Liquid Biopsy Technology 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liquid Biopsy Technology Revenue in 2022
3.5 Liquid Biopsy Technology Key Players Head office and Area Served
3.6 Key Players Liquid Biopsy Technology Product Solution and Service
3.7 Date of Enter into Liquid Biopsy Technology 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Liquid Biopsy Technology Breakdown Data by Type
4.1 Global Liquid Biopsy Technology Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Liquid Biopsy Technology Forecasted 麻豆原创 Size by Type (2024-2029)
5 Liquid Biopsy Technology Breakdown Data by Application
5.1 Global Liquid Biopsy Technology Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Liquid Biopsy Technology Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Liquid Biopsy Technology 麻豆原创 Size (2018-2029)
6.2 North America Liquid Biopsy Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Liquid Biopsy Technology 麻豆原创 Size by Country (2018-2023)
6.4 North America Liquid Biopsy Technology 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liquid Biopsy Technology 麻豆原创 Size (2018-2029)
7.2 Europe Liquid Biopsy Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Liquid Biopsy Technology 麻豆原创 Size by Country (2018-2023)
7.4 Europe Liquid Biopsy Technology 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liquid Biopsy Technology 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Liquid Biopsy Technology 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Liquid Biopsy Technology 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Liquid Biopsy Technology 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liquid Biopsy Technology 麻豆原创 Size (2018-2029)
9.2 Latin America Liquid Biopsy Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Liquid Biopsy Technology 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Liquid Biopsy Technology 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liquid Biopsy Technology 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Liquid Biopsy Technology 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Liquid Biopsy Technology 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Liquid Biopsy Technology 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Exact Sciences
11.1.1 Exact Sciences Company Detail
11.1.2 Exact Sciences Business Overview
11.1.3 Exact Sciences Liquid Biopsy Technology Introduction
11.1.4 Exact Sciences Revenue in Liquid Biopsy Technology Business (2018-2023)
11.1.5 Exact Sciences Recent Development
11.2 Guardant Health
11.2.1 Guardant Health Company Detail
11.2.2 Guardant Health Business Overview
11.2.3 Guardant Health Liquid Biopsy Technology Introduction
11.2.4 Guardant Health Revenue in Liquid Biopsy Technology Business (2018-2023)
11.2.5 Guardant Health Recent Development
11.3 Natera
11.3.1 Natera Company Detail
11.3.2 Natera Business Overview
11.3.3 Natera Liquid Biopsy Technology Introduction
11.3.4 Natera Revenue in Liquid Biopsy Technology Business (2018-2023)
11.3.5 Natera Recent Development
11.4 Bio-Techne
11.4.1 Bio-Techne Company Detail
11.4.2 Bio-Techne Business Overview
11.4.3 Bio-Techne Liquid Biopsy Technology Introduction
11.4.4 Bio-Techne Revenue in Liquid Biopsy Technology Business (2018-2023)
11.4.5 Bio-Techne Recent Development
11.5 LabCorp
11.5.1 LabCorp Company Detail
11.5.2 LabCorp Business Overview
11.5.3 LabCorp Liquid Biopsy Technology Introduction
11.5.4 LabCorp Revenue in Liquid Biopsy Technology Business (2018-2023)
11.5.5 LabCorp Recent Development
11.6 Endress+Hauser
11.6.1 Endress+Hauser Company Detail
11.6.2 Endress+Hauser Business Overview
11.6.3 Endress+Hauser Liquid Biopsy Technology Introduction
11.6.4 Endress+Hauser Revenue in Liquid Biopsy Technology Business (2018-2023)
11.6.5 Endress+Hauser Recent Development
11.7 MDxHealth
11.7.1 MDxHealth Company Detail
11.7.2 MDxHealth Business Overview
11.7.3 MDxHealth Liquid Biopsy Technology Introduction
11.7.4 MDxHealth Revenue in Liquid Biopsy Technology Business (2018-2023)
11.7.5 MDxHealth Recent Development
11.8 MutantDx
11.8.1 MutantDx Company Detail
11.8.2 MutantDx Business Overview
11.8.3 MutantDx Liquid Biopsy Technology Introduction
11.8.4 MutantDx Revenue in Liquid Biopsy Technology Business (2018-2023)
11.8.5 MutantDx Recent Development
11.9 Thermo Fisher Scientific
11.9.1 Thermo Fisher Scientific Company Detail
11.9.2 Thermo Fisher Scientific Business Overview
11.9.3 Thermo Fisher Scientific Liquid Biopsy Technology Introduction
11.9.4 Thermo Fisher Scientific Revenue in Liquid Biopsy Technology Business (2018-2023)
11.9.5 Thermo Fisher Scientific Recent Development
11.10 Norgen Biotek
11.10.1 Norgen Biotek Company Detail
11.10.2 Norgen Biotek Business Overview
11.10.3 Norgen Biotek Liquid Biopsy Technology Introduction
11.10.4 Norgen Biotek Revenue in Liquid Biopsy Technology Business (2018-2023)
11.10.5 Norgen Biotek Recent Development
11.11 Nucleix
11.11.1 Nucleix Company Detail
11.11.2 Nucleix Business Overview
11.11.3 Nucleix Liquid Biopsy Technology Introduction
11.11.4 Nucleix Revenue in Liquid Biopsy Technology Business (2018-2023)
11.11.5 Nucleix Recent Development
11.12 OraSure Technologies
11.12.1 OraSure Technologies Company Detail
11.12.2 OraSure Technologies Business Overview
11.12.3 OraSure Technologies Liquid Biopsy Technology Introduction
11.12.4 OraSure Technologies Revenue in Liquid Biopsy Technology Business (2018-2023)
11.12.5 OraSure Technologies Recent Development
11.13 Qiagen
11.13.1 Qiagen Company Detail
11.13.2 Qiagen Business Overview
11.13.3 Qiagen Liquid Biopsy Technology Introduction
11.13.4 Qiagen Revenue in Liquid Biopsy Technology Business (2018-2023)
11.13.5 Qiagen Recent Development
11.14 Bio-Rad Laboratories
11.14.1 Bio-Rad Laboratories Company Detail
11.14.2 Bio-Rad Laboratories Business Overview
11.14.3 Bio-Rad Laboratories Liquid Biopsy Technology Introduction
11.14.4 Bio-Rad Laboratories Revenue in Liquid Biopsy Technology Business (2018-2023)
11.14.5 Bio-Rad Laboratories Recent Development
11.15 Biocartis
11.15.1 Biocartis Company Detail
11.15.2 Biocartis Business Overview
11.15.3 Biocartis Liquid Biopsy Technology Introduction
11.15.4 Biocartis Revenue in Liquid Biopsy Technology Business (2018-2023)
11.15.5 Biocartis Recent Development
11.16 NeoGenomics
11.16.1 NeoGenomics Company Detail
11.16.2 NeoGenomics Business Overview
11.16.3 NeoGenomics Liquid Biopsy Technology Introduction
11.16.4 NeoGenomics Revenue in Liquid Biopsy Technology Business (2018-2023)
11.16.5 NeoGenomics Recent Development
11.17 Sysmex Inostics
11.17.1 Sysmex Inostics Company Detail
11.17.2 Sysmex Inostics Business Overview
11.17.3 Sysmex Inostics Liquid Biopsy Technology Introduction
11.17.4 Sysmex Inostics Revenue in Liquid Biopsy Technology Business (2018-2023)
11.17.5 Sysmex Inostics Recent Development
11.18 Menarini Silicon Biosystems
11.18.1 Menarini Silicon Biosystems Company Detail
11.18.2 Menarini Silicon Biosystems Business Overview
11.18.3 Menarini Silicon Biosystems Liquid Biopsy Technology Introduction
11.18.4 Menarini Silicon Biosystems Revenue in Liquid Biopsy Technology Business (2018-2023)
11.18.5 Menarini Silicon Biosystems Recent Development
11.19 Biocept
11.19.1 Biocept Company Detail
11.19.2 Biocept Business Overview
11.19.3 Biocept Liquid Biopsy Technology Introduction
11.19.4 Biocept Revenue in Liquid Biopsy Technology Business (2018-2023)
11.19.5 Biocept Recent Development
11.20 ANGLE plc
11.20.1 ANGLE plc Company Detail
11.20.2 ANGLE plc Business Overview
11.20.3 ANGLE plc Liquid Biopsy Technology Introduction
11.20.4 ANGLE plc Revenue in Liquid Biopsy Technology Business (2018-2023)
11.20.5 ANGLE plc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Exact Sciences
Guardant Health
Natera
Bio-Techne
LabCorp
Endress+Hauser
MDxHealth
MutantDx
Thermo Fisher Scientific
Norgen Biotek
Nucleix
OraSure Technologies
Qiagen
Bio-Rad Laboratories
Biocartis
NeoGenomics
Sysmex Inostics
Menarini Silicon Biosystems
Biocept
ANGLE plc

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.